Podcasts about Relation

This week on the WHOOP Podcast, WHOOP Global Head of Human Performance, Principal Scientist, Dr. Kristen Holmes sits down with Dr. Gina Poe, neurobiologist and expert in REM sleep and memory consolidation. Together, Dr. Holmes and Dr. Poe unpack what actually happens when you're asleep and why sleep is essential not just for memory, but emotional resilience, longevity, and high performance. This episode breaks down the different stages of sleep and how they reshape the brain, regulate the nervous system, and actually clean the brain. Dr. Holmes and Dr. Poe provide insight on daily habits to optimize sleep quality, including timing, exercise, and stress regulation.(00:23) Introduction to Dr. Gina Poe(00:58) Dr. Poe's Journey to Sleep Research (06:58) Sleep Timing in Relation to The Body's Physiological Rhythm(12:29) Sleep Pressure and Melatonin Production(14:52) REM Sleep Reshaping the Brain Each Night(21:03) Effects of Short Sleep Cycles (30:17) Relationship Between Skipped Sleep Cycles and Neurodegenerative Disease(31:36) The Importance of Sleep Spindles & Exercise on Sleep Performance(40:46) How Sleep Spindles Change Over A Lifespan(43:44) Daily Practices That Promote Healthy Sleep (49:15) Shift Work, Sleep Cycles, & Human Growth Hormone(55:01) Metabolism and Sleep Cycles: What Happens To The Body's Energy Storage(59:21) Dr. Poe's Dream Sleep Study(01:01:09) What Healthy Sleep Looks Like(01:05:38) Rapid Fire TakeawaysDr. Gina Poe:XRelated Episodes:The Science of Stress & Sleep For Optimal Performance with Dr. Bill von HippelSpotifyAppleYouTubeHow to Sleep Better with Dr. Shelby HarrisSpotifyAppleYouTubeSupport the showFollow WHOOP: www.whoop.com Trial WHOOP for Free Instagram TikTok YouTube X Facebook LinkedIn Follow Will Ahmed: Instagram X LinkedIn Follow Kristen Holmes: Instagram LinkedIn Follow Emily Capodilupo: LinkedIn

Retrouvez la boutique LEGEND ➡️: https://shop.legend-group.fr/Merci à Dominique de Villepin d'être venu nous voir chez LEGEND ! L'ancien premier ministre est venu se confier sur son enfance à l'étranger, la mort de son frère, ses années auprès de Jacques Chirac et son regard sur la politique d'aujourd'hui en France.Retrouvez son livre “Le pouvoir de dire non” chez Flammarion ➡️: https://amzn.to/4latqsMSuivez Dominique de Villepin sur Instagram ⬇️: https://www.instagram.com/dominique_devillepin/Ainsi que sur Facebook ➡️: https://www.facebook.com/pagevillepin/Retrouvez l'interview complète sur YouTube ➡️ https://youtu.be/yKHrWFgmg7sPour toutes demandes de partenariats : legend@influxcrew.comRetrouvez-nous sur tous les réseaux LEGEND !Facebook : https://www.facebook.com/legendmediafrInstagram : https://www.instagram.com/legendmedia/TikTok : https://www.tiktok.com/@legendTwitter : https://twitter.com/legendmediafrSnapchat : https://t.snapchat.com/CgEvsbWV Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Dans cet épisode, je partage ce que l'absence de figure paternelle a créé en moi — les manques, les forces, les questions.Pas pour chercher la pitié, mais pour parler de ce silence qu'on évoque rarement.Un récit personnel, intime, nuancé. Parce qu'on peut se forger autrement.

Come to a Dehoarding Accountability Zoom Session: http://www.overcomecompulsivehoarding.co.uk/ticket Subscribe to the podcast: https://www.overcomecompulsivehoarding.co.uk/subscribe Podcast show notes, links and transcript: http://www.overcomecompulsivehoarding.co.uk/  In this episode, I unpack the myth of laziness and why it's such a damaging label for people with hoarding disorder. I'll break down how blaming ourselves or others for being “lazy” ignores the real barriers - like overwhelm, poor mental health, executive dysfunction and more - and just piles on more shame. Let's get honest about what's actually holding us back and why reframing this idea matters. The Myth of Laziness in Relation to Hoarding Revisiting a previous episode's question: Are hoarders lazy? Arguments against the idea (hoarded homes require more energy to live in, etc.) The aversion to external intervention reveals deeper issues than laziness Societal attitudes towards rest and productivity Internalised and external accusations of laziness The damaging effects: shame, isolation, distress Understanding Hoarding as a Mental Health Issue Hoarding as a coping method for difficult emotions Judgments of laziness overlook the disorder's complexity and nuance Such labels add barriers to seeking help and reinforce stigma Consequences of Labelling People who Hoard (or Ourselves) as Lazy Shame and self-criticism deepen the problem Laziness as a simplistic explanation that ignores underlying issues Possible root causes: executive dysfunction, decision-making difficulties, emotional attachment to items, avoidance, depression, physical disability, etc. The Harmful Cultural Narrative Around Laziness Societal pressures to be constantly productive Inaccuracies of the “we all have the same 24 hours” myth Differences in time and capability due to systemic inequalities Examples: physical ability, mental health, neurodivergence, responsibilities, discrimination Moral and Social Implications of the “Lazy” Label Care tasks are morally neutral (reference to KC Davis, episode 82) The negative cycle: shame leads to paralysis, makes it harder to seek help and make progress Laziness label used as a justification for lack of societal support Political and social consequences for marginalised groups Importance of community, support, and helping each other The Danger of Linking Self-Worth to Productivity The toxic culture of non-stop productivity and hustling Problems with feeling guilty for resting The spiral of self-worth being tied to continuous output The Limiting Nature of the Laziness Concept It shuts down further exploration of underlying problems Missed opportunities for self-compassion, empathy, and effective assistance Underlying Reasons for Struggles That Are Mistaken for Laziness Lack of motivation: exhaustion, depression, overwhelm Overwhelm due to the scale of the task Executive dysfunction (planning, initiating, processing tasks) Fear (of the process, of making wrong decisions, of consequences) Fatigue, burnout, and mental health struggles Being practically or emotionally stuck, lacking skills or knowledge Societal Structures and Individual Blame Blame placed on individuals ignores wider systemic and commercial influences Industries profit from reinforcing personal inadequacy (beauty industry analogy, storage solutions) The cycle of self-blame, shame, and attempts to “fix” via consumerism Breaking the Cycle and Moving Forward Recognising the myth of laziness enables real progress Compassion, curiosity, and support as healthier responses Encouragement for self-acceptance and seeking genuine solutions Buy your copy of Everything You Need to Know About Hoarding by Dr Lynne Drummond at cambridge.org/EverythingHoarding, and get 20% off with the discount code HOARDING20. #ad Links Podcast ep 57: Are hoarders lazy? I think you'd be surprised… Podcast ep 82: Dehoarding when you're drowning with KC Davis of Struggle Care Podcast ep 112: Executive function, executive dysfunction and hoarding with Dr Jan Eppingstall Podcast ep 186: 10 executive dysfunction tips and tricks to help people who hoard, whether we have ADHD or are neurodivergent or not – Hoarding Awareness Week 2025 Podcast ep 183: ADHD, executive dysfunction and creating hacks and systems to reduce clutter chaos, with Carrie Lagerstedt Podcast ep 162: From Fibble to Focus: Defibble your executive dysfunction with Jo Cavalot Podcast ep 188: 12 ways to make decision-making easier (and why people who hoard find it so hard to make decisions in the first place!) Podcast ep 139: Chronic disorganisation with Jo Cooke of Hoarding Disorders UK Podcast ep 107: Things that look like hoarding but aren't: ADHD, depression, autism, OCD, OCPD and more Enough, the Podcast Come to a Dehoarding Accountability Zoom session: Accountability Booking Form Website: Overcome Compulsive Hoarding Become a Dehoarding Darling Submit a topic for the podcast to cover Questions to ask when dehoarding: https://www.overcomecompulsivehoarding.co.uk/podquestions Instagram: @thathoarderpodcast Twitter: @ThatHoarder Mastodon: @ThatHoarder@mastodon.online TikTok: @thathoarderpodcast Facebook: Overcome Compulsive Hoarding with That Hoarder Pinterest: That Hoarder YouTube: Overcome Compulsive Hoarding with That Hoarder Reddit: Overcome Compulsive Hoarding with That Hoarder subreddit Help out: Support this project Sponsor the podcast Subscribe to the podcast Subscribe to the podcast here

REDIFF - Jack Unterweger, célèbre écrivain, journaliste et exemple de réhabilitation après 15 ans de prison, a dupé tout le monde, tuant 11 femmes après sa sortie de prison. Astrid Wagner, avocate à Vienne en Autriche, est la dernière femme a avoir vécu avec elle. Elle raconte leur histoire. Dans ce podcast inédit, découvrez un supplément de l'émission de "L'heure du crime". Questions oubliées, ou qui n'ont pas pu être posées à l'antenne, Justine Vignaux reste en studio avec l'invité(e) de Jean-Alphonse Richard, pour en savoir plus sur l'affaire du jour.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

This is a special edition of conscient roundtable featuring Lara Felsing, Adrian Avendaño, Hildegard Westerkamp, Toni-Leah C. Yake as part of the Listening in Relation gathering at Emily Carr University of Art and Design on March 21-23, 2025 on the traditional, ancestral, and unceded territories of the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and səlilwətaɬ (Tsleil-Waututh) Nations, also known as Vancouver. Warm thanks to Julie  Andreyev of Emily Carr University, Barbara Adler of The Only Animal, the Canadian Association for Sound Ecology (CASE), Raphael Zen (who is a guest on conscient e228), and all the roundtable participants. Show notes generated by Whisper Transcribe AIAction PointsExplore the role of listening in decolonizing creative practices and challenging colonial narratives.Recognize the importance of land acknowledgments as active opportunities to listen to and honor Indigenous requests.Integrate personal and ancestral knowledge into artistic processes to foster relationality with the land and more-than-human beings.Reflect on the ethical implications of technology use in art, considering environmental impact and responsible creation.Embrace silence and slow down to connect with inner wisdom and speak from the heart.Story PreviewWhat does it truly mean to listen? Dive into an exploration of decolonization through sound, art, and personal reflections. Hear from artists who are reshaping their creative practices to honor the land, ancestors, and the unseen voices that guide them.Chapter Summary00:00 Introduction to Listening in Relation02:20 Keynote Panel Overview06:48 Artistic Journeys and Ancestral Connections29:58 Dream Technology and Cultural Expression41:27 Identity, Land, and Heritage50:01 Sonic Memories and Cultural Practices57:04 Sacred Spaces and Cultural Resilience01:03:05 Reflections on Cultural Action and Belonging01:11:09 The Power of Listening and Silence01:16:10 Technology, Creativity, and Environmental Impact01:35:20 Closing Thoughts and Community EngagementFeatured QuotesLara Felsing : ‘I think about listening in my practice as being receptive to concerns that are happening on the land.'Toni Leah C. Yakes : ‘When you're asking where you're from, you're actually asking: What clay are you made of? or What earth are you made of?'Hildegard Westerkamp : ‘Listening was always the base from where I functioned. Listening always brought us back to ground.'Behind the StoryThe ‘Listening in Relation' event at Emily Carr University of Art and Design brought together artists and thinkers to explore the critical role of listening and decolonization. This episode captures the keynote panel of that event, exploring how artists are actively engaging with sound, memory, and the land to challenge colonial narratives and foster deeper connections. The discussion highlights the delicate balance between technology, creativity, and environmental responsibility, prompting a reflection on our relationship with the world around us. *END NOTES FOR ALL EPISODESHey conscient listeners, I've been producing the conscient podcast as a learning and unlearning journey since May 2020 on un-ceded Anishinaabe Algonquin territory (Ottawa). It's my way to give back.In parallel with the production of the conscient podcast and its francophone counterpart, balado conscient, I I publish fee ‘a calm presence' Substack see https://acalmpresence.substack.com.Your feedback is always welcome at claude@conscient.ca and/or on social media: Facebook, Instagram, Linkedin, Threads, BlueSky, Mastodon, Tik Tok, YouTube and Substack.I am grateful and accountable to the earth and the human labour that provided me with the privilege of producing this podcast, including the toxic materials and extractive processes behind the computers, recorders, transportation systems and infrastructure that made this production possible. Claude SchryerLatest update on July 8, 2025

In today's episode, I'm joined by the brilliant Logan Ury—behavioral scientist, dating coach, and author of How to Not Die Alone. We dive deep into the messy and sometimes painfully confusing world of modern dating. From the myths that keep us single to the science-backed truths about real lasting connection, Logan shares tons of actionable advice. We chat about how vulnerability and timing play crucial roles in finding a great match, why dating apps feel so overwhelming, what people think they want versus what actually leads to a long-term partnership, her “Three Dating Tendencies” framework, and how to stop self-sabotaging when it comes to finding your forever person. Whether you're single and swiping, newly partnered, or just relationship-curious, this conversation is packed with insights that will totally reframe how you approach dating, relationships, and yourself. We will also be discussing the romantic comedy movie that just came out: The Materialist. If you don't want to hear spoilers about the movie's ending, stop listening when Liz gives a heads-up—around 44:40 on Spotify video or after the second ad break on Apple audio—and come back after you've seen it to hear Liz's and Logan's different hot takes! In this episode, we get into: How to date like a scientist Finding your true deal-breakers Emotional intelligence & dating Money & dating Predictors of long-term success The stress test Physical expectations & dating If love is enough Modern masculinity & modern femininity Relation shopping vs. relation shipping Hot takes on the materialist movie For more from Logan Ury, find her on Instagram @loganury or online at www.loganury.com to check out her newsletter and matchmaking services. Read her book, How To Not Die Alone. Ready to uplevel every part of your life? Order Liz's book 100 Ways to Change Your Life: The Science of Leveling Up Health, Happiness, Relationships & Success now!  Connect with Liz on Instagram @lizmoody or online at www.lizmoody.com. Subscribe to the substack by visiting https://lizmoody.substack.com/welcome. To join The Liz Moody Podcast Club Facebook group, go to www.facebook.com/groups/thelizmoodypodcast. This episode is brought to you completely free thanks to the following podcast sponsors: Shopify: Sign up for a one-dollar-per-month trial period at shopify.com/lizm.  Maui Nui: Head to mauinuivenison.com/LIZ to secure your access to a limited collection of Liz's favorite nutrient-dense wildly delicious meat cuts and products.  LMNT: Go to DrinkLMNT.com/LizMoody to get a free LMNT sample pack with any order. Evlo: Head to EvloFitness.com and use code LIZMOODY to get 6 full weeks completely FREE. The Liz Moody Podcast cover art by Zack. The Liz Moody Podcast music by Alex Ruimy. Formerly the Healthier Together Podcast.  This podcast and website represents the opinions of Liz Moody and her guests to the show. The content here should not be taken as medical advice. The content here is for information purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions. The Liz Moody Podcast Episode 343. Learn more about your ad choices. Visit megaphone.fm/adchoices

Merci Guillaume !Son Linkedin À découvrir :

Lorsque plus rien ne bouge, lorsque ton autre malgré ta communication, malgré ta patience, n'avance pas, il est parfois nécessaire d'aller vers cette étape du deuil de la relation.Je t'explique pourquoi? Je te souhaite une belle écoute. Avec cœur,Marie————————————————

Can what's on your plate rewire your brain?In this mind-altering episode, I sit down with Dr. Uma Naidoo—Harvard-trained psychiatrist, nutritional psychiatrist, and author of This Is Your Brain on Food—to uncover the hidden science behind how food fuels (or fails) your mental health. From anxiety-busting berries to brain-boosting spices, we explore how your next meal could be your next therapy session.Whether you're battling brain fog, burnout, or just want to feel better, this episode rewrites the rules of what eating for health really means. Tune in—because what you eat might just be the missing piece to your peace of mind.Full episode Important links:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ryan Fernando App⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Diet plan ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Blood test⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cancer screening⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Studies of the podcast⁠⁠⁠⁠⁠⁠Socials:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Link tree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Products to purchase:-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Collagen ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1CHAZE 1500g⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1CHAZE 750g ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Books ⁠⁠⁠⁠⁠Find Uma here: Instagram YouTube Website Facebook LinkedIn Time Stamps00:00 - Trailer 2:00 - Introduction3:14 - What is nutrition Psychiatry?4:19 - Uma Naidoo's passion for nutrition 9:05 - Can food act as therapy?11:00 - SAW approach 13:12- Link between food and brain16:09 - Can psychological problems change gut bacteria?17:47 - Ideal anti-anxiety meal 21:54 - Importance of paring foods23:14- Are supplements actually needed?25:12 - Age to start healthy eating30:35 - Advice to youngsters 32:54 - Hacks to eat better36:05 -Importance of sleep43:00 - How to reset the brain48:00 - Power of magnesium52:51 - All about the gut microbiome 56:22- Importance of fermented foods1:00:55- Does fasting help?1:02:36- Will doctors ever start prescribing food?1:04:00 - Rapid Fire 1:10:05 - Outro

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

We've all made cringeworthy mistakes in the quest for love (some of us more than others—ahem, Jinah). But according to our guest, there are FIVE big dating missteps that people repeat again and again… and they might just be what's keeping you single. This week, we're joined by dating coach, relationship strategist, and host of the YouTube show Dating Makeover, Lana Ricco (@lana.ricco). She's currently writing a book titled The 5 Biggest Dating Mistakes Keeping You Single (and How to Fix Them)—but lucky for you, she's breaking them all down for us right here. Spoiler: Jinah's guilty of pretty much every single one.

Lorsqu'on est célib depuis un moment déjà, la question est légitime :  suis-je faite pour être en couple exclusif ?  Ou ne serait-ce pas le moment de succomber aux “nouvelles“ modes relationnelles qui font vendre les magazines ?    Dans cet épisode tu vas découvrir :  Pourquoi ces nouvelles modes n'ont rien de nouveau, Comment elles te détournent de ce que toi tu veux vraiment.  La vraie raison pour laquelle elles sont si attirantes.   Tu vas apprendre :  C'est en réalité une fuite. Elles sont le reflet d'une société qui est complètement perdu.  Ce qui te va à toi.   Bonne écoute.  Fanny.   Épisode mentionné : 294 - Sommes-nous fait pour rester ensemble toute une vie ?    Reçois gratuitement la liste de tous les épisodes qui parlent de vivre ta vie idéale, prendre des décisions alignées & prendre ta place : ici   Découvre mon livre, mes cours. :  Livre broché ou Kindle Livre audio Cours et programmes Spécialisation schéma amoureux Retrouve-moi sur mes réseaux et partage-moi tes réalisations suite aux épisodes : Instagram Facebook

VILKA: Celina & Thomas LinderholmYRKE: Advokat/IngenjörOM: Att leva i en icke-monogam relation – så funkar det i praktiken (för dem!), så gick det till när de tog steget, svartsjuka, system för fest, att ha svårt att hitta dejter på apparna, öppenhet med vänner och kollegor, skillnaden mellan poly- och ickemonogami, familjeliv och givetvis en hel del om att inspirera andra monogama par att våga testa – kanske även Kristoffer och hans fru Cecilia?För vidare relationstips av Celina & Thomas:www.youmeand.se och InstagramSAMTALSLEDARE: Cecilia Rada & Kristoffer TriumfPRODUCENT: Mattias ÅsénKONTAKT: varvet@triumf.se och Instagram Hosted on Acast. See acast.com/privacy for more information.

Part 2 - Sovereign Debt Restructuring in relation to International Law

Part 1 - Sovereign Debt Restructuring in relation to International Law

If bladder issues in menopause are keeping you from jumping for bone density or for jumping for joy. Or if laughing and sneezing or a need to consider hydration needs against access to a bathroom are real life and every day concerns you… we've got you today.  Bladder issues in menopause don't need to keep you from activities, and they may come with signs and symptoms that aren't the obvious urgency, burning or leakage. The information here about testing beyond traditional options just might make you want to re-listen and share this one.    My Guest: Dr Kelly McCann is a board certified internist and pediatrician specializing in functional, integrative and environmental medicine. She graduated Brown undergrad, Tulane Med School, fellowship in Integrative Medicine at the University of Arizona. Her medical practice, the Spring Center, is located in Southern California. She hosted virtual summits on MCAS and can be found on many podcasts, summits and @drkellymccann.   Questions We Answer in This Episode: [00:09:09] What is a bacterial biofilm and how does that relate to bladder issues in women? [00:08:21] How do you know if you have a biofilm colonization? [00:13:26] Can you explain the testing technology and how it differs from a urinalysis and urine culture? [00:25:09] Other than UTIs and bladder issues, what might be some other signs that bacterial biofilms might be an issue?  [00:26:55] Are there other things that we should understand about this? (often associated with hypercoagulability which can mean an increased risk for heart disease) [00:30:58] Are there other options before or instead of antibiotics? If you personally got results back suggesting you do have bacteria, would you go the route of herbs or antibiotics?  [00:35:00] Cost of the test? And is it covered?    Bacterial Biofilm as Bladder Issues in Menopause   What is a Bacterial Biofilm? Mucus-like structures where bacteria live, can be found in the mouth, nose, GI tract, vagina, etc. These bacterial “homes” protect microbes from detection in standard lab tests. That means you can have symptoms, but your test results still show “normal.”   What is Next Generation Sequencing? Gives a complete and accurate picture of what's causing  your symptoms, even when your urinalysis and cultures are ‘normal'. Procedure: Scans the DNA of everything present in your sample (e.g. urine). Matches it to a vast DNA library of known organisms. Identifies exactly which microbes are in your bladder, how many, and in what percentages. Recommends treatment options by checking the medical literature for which antibiotics are effective against each bacteria. MicroGenDX does this test.   Signs You Might Have Biofilm Colonization: Chronic bladder symptoms (urgency, frequency, burning) without a confirmed UTI Recurrent UTIs that don't resolve or keep returning “Normal” urine tests but ongoing discomfort Other unexplained inflammation-driven symptoms like fatigue, rashes, headaches, joint pain, and more.   Relation to Heart Disease: Bacteria can travel from brushing your teeth and can end up in your coronary arteries and bladder. Biofilms can trigger clot formation for individuals who are genetically predisposed to forming clots or fibrin mesh. Systemic inflammation risk for individuals with low-level bacterial colonization that their body   Connect with Kelly: Website - Dr. Kelly McCann Website - The Spring Center Facebook - Dr. Kelly McCann Instagram - @drkellymccann    Other Episodes You Might Like: Previous Episode - Solving Sleep Issues with CBD and Other Perimenopause Symptom Solutions Next Episode - What Stem Cell Therapy Taught Me About Recovery, Mindset, and Reinventing Downtime More Like This - True Core Confidence: Revolutionizing Pelvic Floor Fitness After 40   Resources: Short & Easy Exercise videos in this 5 Day Flip Challenge. Don't know where to start? Book your Discovery Call with Debra.  

durée : 00:06:26 - L'invité de 6h20 - La Défenseure des Droits, Claire Hedon, était l'invitée de France Inter ce mardi pour détailler l'enquête sur les relations entre les forces de l'ordre et la population. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

As expected, the flood gates have now opened when it comes to allegations made against Diddy and in this epiosde, we take a look at what April Lampros says happened to her at the hands of Diddy.The NYC Gender Motivated Violence Act (GMVA), codified in N.Y.C. Administrative Code §§ 8-901 et seq., is a law enacted by New York City to address and provide legal remedies for gender-motivated violence. Here are some key points about the Act:Purpose: The GMVA aims to provide a civil remedy for individuals who are victims of gender-motivated violence. This type of violence is defined as a crime of violence committed because of gender or on the basis of gender.Definitions:Crime of Violence: The Act defines a "crime of violence" as any act or series of acts that would constitute a misdemeanor or felony under the penal law of New York State.Gender-Motivated: A crime is considered "gender-motivated" if it is committed, at least in part, because of the victim's gender or on the basis of gender.Civil Action:Victims of gender-motivated violence have the right to file a civil lawsuit against the perpetrator.The Act allows victims to seek compensatory and punitive damages, as well as attorney's fees and costs.Statute of Limitations:There is a seven-year statute of limitations for filing a civil action under the GMVA, which begins from the date of the last act of gender-motivated violence.Burden of Proof:In a civil action under the GMVA, the plaintiff must prove by a preponderance of the evidence that the violence was gender-motivated.Relation to Other Laws:The GMVA is intended to complement existing laws and does not preclude victims from seeking other legal remedies available under state or federal law.(commercial at 7:17)to contact me:bobbycapucci@protonmail.comsource:not_assigned_april_lampros_v_sean_combs_et_al_summons___complaint_1_1716553445.pdf (documentcloud.org)

As expected, the flood gates have now opened when it comes to allegations made against Diddy and in this epiosde, we take a look at what April Lampros says happened to her at the hands of Diddy.The NYC Gender Motivated Violence Act (GMVA), codified in N.Y.C. Administrative Code §§ 8-901 et seq., is a law enacted by New York City to address and provide legal remedies for gender-motivated violence. Here are some key points about the Act:Purpose: The GMVA aims to provide a civil remedy for individuals who are victims of gender-motivated violence. This type of violence is defined as a crime of violence committed because of gender or on the basis of gender.Definitions:Crime of Violence: The Act defines a "crime of violence" as any act or series of acts that would constitute a misdemeanor or felony under the penal law of New York State.Gender-Motivated: A crime is considered "gender-motivated" if it is committed, at least in part, because of the victim's gender or on the basis of gender.Civil Action:Victims of gender-motivated violence have the right to file a civil lawsuit against the perpetrator.The Act allows victims to seek compensatory and punitive damages, as well as attorney's fees and costs.Statute of Limitations:There is a seven-year statute of limitations for filing a civil action under the GMVA, which begins from the date of the last act of gender-motivated violence.Burden of Proof:In a civil action under the GMVA, the plaintiff must prove by a preponderance of the evidence that the violence was gender-motivated.Relation to Other Laws:The GMVA is intended to complement existing laws and does not preclude victims from seeking other legal remedies available under state or federal law.(commercial at 7:17)to contact me:bobbycapucci@protonmail.comsource:not_assigned_april_lampros_v_sean_combs_et_al_summons___complaint_1_1716553445.pdf (documentcloud.org)

As expected, the flood gates have now opened when it comes to allegations made against Diddy and in this epiosde, we take a look at what April Lampros says happened to her at the hands of Diddy.The NYC Gender Motivated Violence Act (GMVA), codified in N.Y.C. Administrative Code §§ 8-901 et seq., is a law enacted by New York City to address and provide legal remedies for gender-motivated violence. Here are some key points about the Act:Purpose: The GMVA aims to provide a civil remedy for individuals who are victims of gender-motivated violence. This type of violence is defined as a crime of violence committed because of gender or on the basis of gender.Definitions:Crime of Violence: The Act defines a "crime of violence" as any act or series of acts that would constitute a misdemeanor or felony under the penal law of New York State.Gender-Motivated: A crime is considered "gender-motivated" if it is committed, at least in part, because of the victim's gender or on the basis of gender.Civil Action:Victims of gender-motivated violence have the right to file a civil lawsuit against the perpetrator.The Act allows victims to seek compensatory and punitive damages, as well as attorney's fees and costs.Statute of Limitations:There is a seven-year statute of limitations for filing a civil action under the GMVA, which begins from the date of the last act of gender-motivated violence.Burden of Proof:In a civil action under the GMVA, the plaintiff must prove by a preponderance of the evidence that the violence was gender-motivated.Relation to Other Laws:The GMVA is intended to complement existing laws and does not preclude victims from seeking other legal remedies available under state or federal law.(commercial at 7:17)to contact me:bobbycapucci@protonmail.comsource:not_assigned_april_lampros_v_sean_combs_et_al_summons___complaint_1_1716553445.pdf (documentcloud.org)

Sandrine a eu des pensées prémonitoires, notamment une vision troublante concernant un ancien ami qui s'est suicidé. Elle a également évoqué sa relation tendue avec sa sœur, marquée par un éloignement suite à des propos blessants tenus lors d'un Noël. Sandrine ressent le besoin de renouer un lien plus profond avec sa sœur, malgré leurs différences de communication. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.frDistribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

As expected, the flood gates have now opened when it comes to allegations made against Diddy and in this epiosde, we take a look at what April Lampros says happened to her at the hands of Diddy.The NYC Gender Motivated Violence Act (GMVA), codified in N.Y.C. Administrative Code §§ 8-901 et seq., is a law enacted by New York City to address and provide legal remedies for gender-motivated violence. Here are some key points about the Act:Purpose: The GMVA aims to provide a civil remedy for individuals who are victims of gender-motivated violence. This type of violence is defined as a crime of violence committed because of gender or on the basis of gender.Definitions:Crime of Violence: The Act defines a "crime of violence" as any act or series of acts that would constitute a misdemeanor or felony under the penal law of New York State.Gender-Motivated: A crime is considered "gender-motivated" if it is committed, at least in part, because of the victim's gender or on the basis of gender.Civil Action:Victims of gender-motivated violence have the right to file a civil lawsuit against the perpetrator.The Act allows victims to seek compensatory and punitive damages, as well as attorney's fees and costs.Statute of Limitations:There is a seven-year statute of limitations for filing a civil action under the GMVA, which begins from the date of the last act of gender-motivated violence.Burden of Proof:In a civil action under the GMVA, the plaintiff must prove by a preponderance of the evidence that the violence was gender-motivated.Relation to Other Laws:The GMVA is intended to complement existing laws and does not preclude victims from seeking other legal remedies available under state or federal law.(commercial at 7:17)to contact me:bobbycapucci@protonmail.comsource:not_assigned_april_lampros_v_sean_combs_et_al_summons___complaint_1_1716553445.pdf (documentcloud.org)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

As expected, the flood gates have now opened when it comes to allegations made against Diddy and in this epiosde, we take a look at what April Lampros says happened to her at the hands of Diddy.The NYC Gender Motivated Violence Act (GMVA), codified in N.Y.C. Administrative Code §§ 8-901 et seq., is a law enacted by New York City to address and provide legal remedies for gender-motivated violence. Here are some key points about the Act:Purpose: The GMVA aims to provide a civil remedy for individuals who are victims of gender-motivated violence. This type of violence is defined as a crime of violence committed because of gender or on the basis of gender.Definitions:Crime of Violence: The Act defines a "crime of violence" as any act or series of acts that would constitute a misdemeanor or felony under the penal law of New York State.Gender-Motivated: A crime is considered "gender-motivated" if it is committed, at least in part, because of the victim's gender or on the basis of gender.Civil Action:Victims of gender-motivated violence have the right to file a civil lawsuit against the perpetrator.The Act allows victims to seek compensatory and punitive damages, as well as attorney's fees and costs.Statute of Limitations:There is a seven-year statute of limitations for filing a civil action under the GMVA, which begins from the date of the last act of gender-motivated violence.Burden of Proof:In a civil action under the GMVA, the plaintiff must prove by a preponderance of the evidence that the violence was gender-motivated.Relation to Other Laws:The GMVA is intended to complement existing laws and does not preclude victims from seeking other legal remedies available under state or federal law.(commercial at 7:17)to contact me:bobbycapucci@protonmail.comsource:not_assigned_april_lampros_v_sean_combs_et_al_summons___complaint_1_1716553445.pdf (documentcloud.org)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

As expected, the flood gates have now opened when it comes to allegations made against Diddy and in this epiosde, we take a look at what April Lampros says happened to her at the hands of Diddy.The NYC Gender Motivated Violence Act (GMVA), codified in N.Y.C. Administrative Code §§ 8-901 et seq., is a law enacted by New York City to address and provide legal remedies for gender-motivated violence. Here are some key points about the Act:Purpose: The GMVA aims to provide a civil remedy for individuals who are victims of gender-motivated violence. This type of violence is defined as a crime of violence committed because of gender or on the basis of gender.Definitions:Crime of Violence: The Act defines a "crime of violence" as any act or series of acts that would constitute a misdemeanor or felony under the penal law of New York State.Gender-Motivated: A crime is considered "gender-motivated" if it is committed, at least in part, because of the victim's gender or on the basis of gender.Civil Action:Victims of gender-motivated violence have the right to file a civil lawsuit against the perpetrator.The Act allows victims to seek compensatory and punitive damages, as well as attorney's fees and costs.Statute of Limitations:There is a seven-year statute of limitations for filing a civil action under the GMVA, which begins from the date of the last act of gender-motivated violence.Burden of Proof:In a civil action under the GMVA, the plaintiff must prove by a preponderance of the evidence that the violence was gender-motivated.Relation to Other Laws:The GMVA is intended to complement existing laws and does not preclude victims from seeking other legal remedies available under state or federal law.(commercial at 7:17)to contact me:bobbycapucci@protonmail.comsource:not_assigned_april_lampros_v_sean_combs_et_al_summons___complaint_1_1716553445.pdf (documentcloud.org)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

As we head into the solstice- that moment when the sun stands still—whether you're in the northern hemisphere where we have the longest day, or the southern, where it's the longest night—this solstice feels like a moment of transformation. The world is turning over, turning a page. The old system is visibly—palpably—breaking apart. A new system will arise from the ashes, because there is always going to be a system. The question is what it looks like, works like, feels like. We are a prosocial, communitarian species, but our culture has shattered from our knowing of our integral place in the All That Is, so it's possible we might end up with a system predicated on hatred, underpinned by fear, where a small number of incredibly frightened people let their traumatised parts run a scorched earth policy in an effort to hold back everything of which they are most afraid, but I am increasingly hopeful that what we're seeing in places is the extinction burst of the old system: its death throes if you like. As I record this, there has been an estimated turnout in the US for the No Kings rallies of between ten and twelve million. This is an astonishing number. If it's true, it's well within shouting distance of the 3.5% of the total population that was considered a tipping point in previous social movements in our recent history: the abolition of slavery in the UK, the civil rights movement in the US, gay marriage in too many nations to count. The difference is that these numbers are based on a pre-internet age. We genuinely don't know what happens when people can see the images on their phones and realise how many of the people around them share the common values of decency, compassion, integrity, generosity-of-spirit.  So if this is potentially a turning point in the making in the US, how do we make this bigger, grander, more of a global movement?  We know we need total systemic change, but how do we make it happen?  How do we create lasting change in our ways of organising everything from food to water to shelter to education. How do we sort our mess of a governance system so we can find those with the greatest wisdom and give them as much power as they need and no more, at all the levels of our culture? As ever, I think the answer lies in our narratives - when ideas become common currency, then we begin to build them into our visions of how the world is and has been and could be. If we can become bold, evolutionary imagineers and craft stories of a different way of organising, loving, relating, caring…then we can live it into being. Which means we need to know in the marrow of our bones what this feels like. Imagination begins in our perception of the possible and part of the horror of the Trauma culture is the systematic stifling of possibility. From our books to our movies to our TV to our TikTok videos, so much is predicated on Trauma Culture narratives of scarcity, separation and powerlessness.  We are told this is the way the world is. That it is human nature to  lack all morality and engage in zero sum strategies that belittle, disempower and crush everyone around us.  Which it isn't. Nonetheless, predatory Capitalism is designed to keep us from imagining things differently. If we're stressed about earning enough to survive while at the same time being hooked on the things we absolutely have to have to feel better, and are being steadily more sedated by the incessant dopamine drips of social media…then we literally cannot step out into other ways of being. So this is our task now - to wean ourselves off the stuff we neither need nor (really) want; off the dopamine drips, and onto things that make our hearts sing so we can build new stories predicated on connection, agency and sufficiency; stories where we are self-conscious nodes in the web of life, and it's our job to ask 'What do you want of me?', listen to the answers, then carry them out to the best of our ability.  That's it. Easy to say. Harder to do.  But we can boil things down to 9 basic concepts:Three Values: Integrity, Compassion, Generosity-of-SpiritThree Baselines: Clean Air, Clean Water, Clean Soil Three ReWoven Connections: between all parts of Ourselves; ourselves and Each Other; Ourselves and the Web of Life. What happens if every single thing we think or do or say or dream is based in these three sets of three? How would our days change? This isn't going to happen overnight, but we can make the commitment to live by them now. Here. This moment.  It's not going to be easy: changing behaviours never is. But we have baselines to work from.  And we might focus on one at a time.  What happens if Clean Water is our priority? How does it change how we live?  What happens if we make Integrity the heart and soul of every interaction through our days - beginning with ourselves? What does it feel like to commit to re-weaving clean, clear, courageous, compassionate connections between all parts of ourselves, ourselves and each other, ourselves and the More than Human world? Clearly I think the inner work is the foundation of everything, though I am aware that this isn't the case for everyone: if you work better in the outer world, if you'd rather lead with head than heart, that's fine, truly.  Go for it.  Find the Values that speak to you and the Baselines you can work with and go for it.  If the Inner Work speaks more to you then know that we in the west need to heal ten thousand years of Trauma Culture in half a decade. It's been at least that long for some of us since our ancestors knew themselves to be an integral part of the web of life. This is the work of the spiritual warrior. It's going to take astonishing levels of courage and commitment. Nobody is pretending this is easy.  But it is essential.And because this is the water I swim in, I'd like to share the basics of how we might get there. It starts with Grounding - with having a clear sense of our physical presence in the world, the flesh and the bones and the teeth of who we are; with sensing the solid earth beneath us as support, containment, holding, as the reality of who and what we are. When our feet are on the earth, there is nowhere left to fall. When we have a sense of roots going down into the earth, we have connection, holding and an open path from the heart of the earth to our heart. If we connect it on up to the heart-mind of the Universe, we have the three hearts in alignment. Just doing this is huge. But then, as we begin really to live in our bodies, so we can begin to recognise the places where trauma sits; the frozen places, the stuck places, the parts of ourselves that leap to our own defence - and are brilliant and wonderful and creative - but who are probably defending against threats that occurred decades ago, if not longer. We carry generational trauma, civilisational trauma. And the healing is ours to do: the good news is that there's a lot of help out there - that just as we really need it, we're beginning really to get to grips with how healing can happen. One to one work is good if you have the means: the time and the money, but many of us don't - and that doesn't mean we can't do the work.  If you'd like to work in groups there's a huge amount.  We offer Gatherings and the Membership, but there's Listen to Thomas Hübl Mystic Cafe — I'll link to his podcast Point of Relation in the show notes —Tara Brach, Michael Meade, Bill Plotkin, Jon Young…a host of others are offering online work that helps you to reconnect to yourself and the land. You have to find out what helps you best, but there's a lot out there. So we do the inner work. And in doing it, we become the still point in the whirling world that...

Au cœur de la nuit, les auditeurs se livrent en toute liberté aux oreilles attentives et bienveillantes de Valérie Darmon. Pas de jugements ni de tabous, une conversation franche, mais aussi des réponses aux questions que les auditeurs se posent. Un moment d'échange et de partage propice à la confidence pour repartir le cœur plus léger.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Salut salut les roupioupious !Comme vous pouvez le voir sur le logo, je porte fièrement mes cheveux naturels, mais je vous avoue que ça n'a pas toujours été le cas, et je n'ai pas toujours été aussi à l'aise avec cette idée. Pendant longtemps, je n'ai pas su aimer mes cheveux, et pour plusieurs raisons.Dans l'épisode d'aujourd'hui, je reviens sur ma relation avec mes cheveux, comment elle a évolué, les obstacles et freins qu'elle a rencontrés, et enfin l'état des lieux de ce qu'est cette relation aujourd'hui, et comment on est arrivé là.Prenez vos chaises et join the kiki !Créatrices mentionées :La marque Exotic4P: https://exotic4tp.com/fr?srsltid=AfmBOoroEGFQygAeGHy9sjm1UVrV7rs8TJCu70EQj_P6IGzVLCB_GJ3yPodcast - Les anonymes heureux : https://smartlink.ausha.co/lesanonymesheureux/rupture-amoureuse-parlons-des-emotions-post-rupture?fbclid=PAZXh0bgNhZW0CMTEAAaf4ciKBu0p4XSBAw1CO8e6sN7Sb0jPM5kiVdjO6oIC6s8GAhMmJpy6hBxnOJg_aem_8L9p-bXgBwBW574PNVtMowLe blog de Will Liena : https://lafemmensociete.blog/?fbclid=PAZXh0bgNhZW0CMTEAAacySio2NFQBlD_4W6m13Gb8oTnU_mRuGXwiusb-AVAEHdsTCcLuzgRXGQGdZg_aem_fl51Gv_0iDiOraE4d8_5Xw / le blogcastTu peux aussi nous rejoindre sur Instagram, u're gonna love it there ! : https://www.instagram.com/kikiwithnini_/N'hésite pas à partager l'épisode autour de toi, et laisser 5 étoiles si tu as apprécié le moment que t'as passé.Merci pour ton soutien ! *clin d'oeil clin d'oeil* Nini

Pour déverrouiller l'épisode en intégral, rejoins le social club en t'abonnant ici : https://buy.stripe.com/14k4gi5JQ6AQaMofTu auras ainsi accès :-à tous les longues interviews en preview (48h avant) et en intégralité -à tous les épisodes avec une clé = le podcast secret (environ 40 épisodes narratifs) pour découvrir comment vivre un quotidien plus aligné avec les valences hautes du beau et du bon-aux 2 newsletters mensuelles dans lesquelles j'ouvre mon jardin secret et partage mes découvertes les plus pépites (hôtels, restaurants, artistes, créatifs, producteurs etc).Tu peux aussi t'abonner uniquement à la newsletter Où est le beau : https://ouestlebeau.kessel.media/?source_referral=None&source_type=user_referralet à celle Où est le bon :https://httpshttpsouestlebeaukesselmediakesselmedia.kessel.media/?source_referral=None&source_type=user_referral&utm_medium=email&utm_source=subscribe_linkDistribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Rencontre avec l'Ambassadeur de France en Australie, Pierre-André Imbert, et la Consule-Générale à Melbourne, Paule Ignatio, pour évoquer les différents événements dynamisant la relation franco-australienne cette semaine à Melbourne.

This update is a statement from Ryan in relation to today's news story in New Zealand covering the discovery of human remains, that could possibly be those of Heidi Paakkonen."It is very important to be clear that I'm not saying they are hers, but only that they could be. And the only way to know for sure is to find them. I'm calling for a second, more detailed search.There is a lot more to this story than just a person finding a skeleton. Obviously there is more evidence at play, when I can I will share this, but for now going public with what I have today was the best way to move the case forward.Thanks for all your patience and understanding with this." - Ryan Support this show http://supporter.acast.com/guilt. Hosted on Acast. See acast.com/privacy for more information.

REDIFF - Christine a rencontré un homme avec lequel elle a tout de suite accroché. Après plusieurs mois de relation, elle lui a proposé, sans lui mettre la pression de passer un week-end à Noël avec sa fratrie. Il a accepté tout de suite. Mais la semaine précédente, il s'est fait porté pâle. Depuis, elle n'a aucune explication. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.frDistribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Is your child struggling with eczema, weight gain, or frequent illnesses? Pediatrician and mom of three, Dr. Ana Maria, reveals how food—not just medicine—transformed her kids' health. Discover the hidden dangers of sugar, the link between nutrition and disease, and the small changes that made a big difference. Packed with real-life stories and doctor-approved tips every parent needs to hear.Press play—your child's healthier future could begin here.Full episodeImportant links:⁠⁠⁠⁠⁠⁠⁠⁠Ryan Fernando App⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Diet plan ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Blood test⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cancer screening⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Studies of the podcast⁠⁠⁠⁠Socials:⁠⁠⁠⁠⁠⁠⁠⁠⁠Link tree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠Products to purchase:-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Collagen ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1CHAZE 1500g⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1CHAZE 750g ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Books ⁠⁠⁠⁠⁠Find Ana here: InstagramYouTube Website Her book Time Stamps: 00:00 - Trailer ⁠ 3:00 - Intro 3:01⁠- Ana's Journey 6:38⁠ - Relation between food and chronic illness11:25- Do C-section babies fall sick more often 15:30 - Do Indians become sicker in America 18:00 - The truth behind pesticides 23:05- Are Eastern families healthier than Western families? 24:56 - Is batch cooking worse than ordering from outside28:58- Why choose Ryan's Nutrition Plan 29:37 - Ancient Secret Western Medicine should take seriously 32:33 - data parents should know 37:14- 3 tips for raising healthy kids44:54- right time to get your child's blood test47:51- genetic test to prevent illness at the root51:11- Can nutrition help in autism 56:12 - Why is it important to discuss bowel movement 1:00:52 - Can a microbiome test help your child 1:03:45 - neurological issues and nutrition 1:06:00 - Playing outside for brain development 1:09:00 - How iPads are making children dumber 1:12:52 - fever, antibiotics and kids' health 1:21:05 - rapid fire

Opening QuestionWhat aspects of the future worry you most? IntroductionThis lesson is primarily drawn from Daniel 2 and 3 and some New Testament parallels, especially Relation 13. Generally, Daniel can be divided into two sections: chs. 1-6 are narrative while chs. 7-12 are more prophetic/visionary. Yet in both chs. 2 and 4, Nebuchadnezzar has dreams. In both, Daniel interprets them for the king, setting the stage for, and giving us clues of interpretation regarding, the later chapters of the book.  It often surprises Bible readers when they learn that the narratives of Daniel are just as significant to helping interpret Revelation ...

Deconstruire nos idées arrêtées et notre relation par rapport au bonheur

Retrouvez la boutique LEGEND ➡️: https://shop.legend-group.fr/Merci à Sneazzy d'être venu nous voir sur LEGEND. De son vrai nom Amine Khemissa, Sneazzy est un rappeur et acteur français. Il s'est fait connaître en tant que membre du groupe 1995, avec Nekfeu et Alpha Wann, avant de poursuivre une carrière solo et se lancer dans le cinéma. Il vient nous voir à l'occasion de la sortie de son nouvel album “Derrière l'horizon”, et nous parler de son enfance, des moments marquants de sa vie, et de la notoriété qu'il a vécue très jeune.Retrouvez son dernière album “Derrière l'horizon” ➡️: https://www.fnac.com/a21123411/Sneazzy-Derriere-l-horizon-CD-albumSuivez Sneazzy sur Instagram ➡️: https://www.instagram.com/sneazzysneazzy/?hl=frRetrouvez l'interview complète sur YouTube ➡️ https://youtu.be/4jdf7OWqbBIPour toutes demandes de partenariats : legend@influxcrew.comRetrouvez-nous sur tous les réseaux LEGEND !Facebook : https://www.facebook.com/legendmediafrInstagram : https://www.instagram.com/legendmedia/TikTok : https://www.tiktok.com/@legendTwitter : https://twitter.com/legendmediafrSnapchat : https://t.snapchat.com/CgEvsbWV Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Hoop draft fellas are back. Tap in.Contact The BAM Connect with us on Twitter, Instagram, Tik Tok, Facebook, and YouTube! Shoot us an email if you have any questions: thebampod1@gmail.com Find us on all podcast streaming platforms here!

reference: Sri Aurobindo and the Mother, Looking from Within, Chapter 4, Ordeals and Difficulties, pg..104This episode is also available as a blog post at https://sriaurobindostudies.wordpress.com/2025/06/11/the-action-of-the-three-gunas-in-relation-to-the-assimilation-of-the-spiritual-force/Video presentations, interviews and podcast episodes are allavailable on the YouTube Channel https://www.youtube.com/@santoshkrinsky871More information about Sri Aurobindo can be found at www.aurobindo.net  The US editions and links to e-book editions of SriAurobindo's writings can be found at Lotus Press www.lotuspress.com

Inès a quitté son mari après dix ans de mariage et deux enfants, car elle se sentait seule à porter les responsabilités familiales. Elle a constaté un manque de communication et de soutien de la part de son mari, qui était passif et peu réactif à ses besoins. Cette décision de séparation lui a permis de retrouver son bien-être personnel. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.frDistribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Don't Whistle At Night welcomes Chris Archer Hosts: Don Yazzie and Darren Yazzie Date: June 6th, 2025 EP: 007 Topic: About Our Guest: Born in Toronto Ontario Canada, into an Occult Family, Chris grew up an Acolyte in the Occult Questioning his own history, as his Indigenous roots purposefully being kept from him until he was a young teen. As a teen, he hitchhiked to British Columbia Canada where he met and lived on the Head of the Lake Reservation to learn about his Okanagan Indigenous Heritage There, He visited with his Great Grandfather who was the Medicine Man and was treated and accepted whole heartedly by those Relation there, as his Great Grandfather "expected" him, although he was a stranger when he arrived. A life long researcher into the Occult, UFOs, Bigfoot and the Global Flood/ Giant Narrative, Chris has been a guest on Will Jevnings Creek Devil many times recounting and discussing his own Bigfoot encounters and the possibilities of these elusive creatures. Chris has also given many talks regarding Theology and Prophecy, North Americas Hidden History, Indigenous Cryptids like the Little People, Bigfoot and Wendigo, Agawa of Lake Superior and the hidden Occult agendas that have played out thru the ages, hidden in plain sight from Europe to the Americas.

Today I share some thoughts on David Lipscomb's use of Scripture in his classic work titled Civil Government: Its Origin, Mission, and Destiny, and the Christian's Relation to It. Although this book is well over a hundred years old, it is surprisingly relevant today as Christians wrestle with how to understand the Bible and how to apply it.

Bhadra gave this talk as part of BAM 2018. He references David Loy's two icebergs and explores how we might revise the Triratana mandala of practice to strengthen our sense of interconnectedness with the world. Given at Bristol Buddhist Centre, 2018. *** Help us keep FBA Podcasts free for everyone! Donate now: https://freebuddhistaudio.com/donate Subscribe to our Free Buddhist Audio podcast: A full, curated, quality Dharma talk, every week. Apple Podcasts: https://podcasts.apple.com/us/podcast/dharmabytes-from-free-buddhist-audio/id416832097 Spotify: https://open.spotify.com/show/4UHPDj01UH6ptj8FObwBfB YouTube: https://www.youtube.com/@FreeBuddhistAudio1967  

Part 1 The Communist Manifesto by Karl Marx SummaryThe Communist Manifesto: Summary Introduction: The Communist Manifesto, authored by Karl Marx and Friedrich Engels and published in 1848, serves as a political pamphlet that outlines the principles of communism and the authors' critique of capitalism. It is divided into four sections, each addressing different aspects of societal development, class struggles, and the concept of communism as a revolutionary response to pervasive inequality. Bourgeois and Proletarians: The manifesto begins by explaining the history of society as a history of class struggles. It delineates two primary classes: the bourgeoisie (the capitalist class who own the means of production) and the proletariat (the working class who sell their labor). The authors argue that the rise of the bourgeoisie during the industrial revolution has led to the oppression of the proletariat. They assert that the capitalist system is inherently exploitative, as the value generated by workers is appropriated by the capitalist class, resulting in vast profits for the bourgeoisie and impoverishment for the proletariat. Proletarians and Communists: In this section, Marx and Engels clarify the role of communists within the broader working-class movement. They emphasize that communists do not form a separate party but rather represent the interests of the proletariat as a whole. The manifesto asserts that communists aim to abolish private property, which they claim is the root of class division and exploitation. They advocate for the transformation of society through collective ownership of the means of production, establishing a classless society that prioritizes human needs over profit. Socialist and Communist Literature: Marx and Engels critique various contemporary socialist and communist literature, exposing their limitations and misconceptions. They criticize utopian socialism for being overly idealistic and lacking a practical political strategy. Instead, they call for a revolutionary approach to dismantle the capitalist system, arguing that the working class must unite to achieve their emancipation. Position of Communists in Relation to the Various Existing Opposition Parties: The final section addresses the political landscape of Europe at the time, discussing the various radical movements against the ruling class. Marx and Engels encourage the workers of the world to rally together in solidarity, emphasizing internationalism and the idea that workers of all nations have a common interest in overthrowing their oppressors. They conclude with a famous rallying cry: "Workers of the world, unite! You have nothing to lose but your chains!" Conclusion: The Communist Manifesto is both a political document and a call to action. It articulates the grievances of the working class under capitalism, while advocating for revolutionary change. Marx and Engels' work has had a profound impact on political thought and movements across the globe, shaping the discourse on class struggle, socialism, and communism.Part 2 The Communist Manifesto AuthorKarl Marx, the German philosopher, economist, and political theorist, co-authored "The Communist Manifesto" with Friedrich Engels. This pivotal political document was first published in London on February 21, 1848. It lays out the principles of Communism and argues for class struggle as the engine of historical and social change. Other Notable Works by Karl Marx:Das Kapital (Capital: Critique of Political Economy) The first volume was published in 1867, and subsequent volumes were published posthumously by Friedrich Engels. "Das Kapital" is considered Marx's major work, in which he critiques the political economy and explores the nature of capitalism.The German Ideology (written in 1845-46, published posthumously in 1932) This work, co-authored...

Hör av er till oss på instagram så kan vi svara på era frågor, hjälpa er med problem och dilemman: @johannanordstrm & @edvintornblom! ursäkta klipps och redigeras av Niklas Runsten @niklasrunsten

Welcome to the Grace in Focus podcast. Today, Kathryn Wright and Ken Yates are talking about Luke 10 and the visit that Jesus made to Mary and Martha's house. Which is most important, serving God, or worshipping Him? Is it possible to overdo our good works of service? How can women (and men) learn balance

Anne Ghesquière reçoit Florentine d'Aulnois-Wang, experte en thérapie de couple et fondatrice de l'Intelligence Amoureuse. Plaisir, jouissance, orgasme, il semblerait que la sexualité n'a jamais été aussi libre et libérée qu'à notre époque. Et pourtant, au-delà de la course au plaisir toujours plus grande ne passons-nous pas à côté d'une vraie connexion à soi, à notre corps et à l'autre ? Florentine d'Aulnois-Wang le clame haut et fort : « La révolution sexuelle n'a pas encore eu lieu ! » Alors si elle n'a pas encore eu lieu, à côté de quoi passons-nous ? Elle nous invite à nous relier à notre être sexuel profond, à lever les obstacles et les peurs et à faire grandir au sein de son couple une sexualité entre sauvage et sacré. Conférencière et experte en thérapie de couple, fondatrice de l'Intelligence Amoureuse elle publie un nouveau livre Les clés de l'intelligence érotique chez Larousse. [REDIFFUSION – BEST OF – MÉTAMORPHOSE]L'épisode #359 a été diffusé, la première fois, le 12 janvier 2023.Quelques citations du podcast avec Florentine d'Aulnois-Wang :"La crise du couple, c'est la croissance qui s'invite.""On a résumé faire l'amour à faire l'orgasme et ce n'est pas la même chose.""Relationner au long cours dans l'amour, ça s'apprend."Thèmes abordés lors du podcast avec Florentine d'Aulnois-Wang : 00:00 Introduction02:42 Existe-t-il une intelligence amoureuse ?03:32 Différences homme/femme05:14 La méthode Imago06:15 Sexualité et connexion07:27 Pourquoi ce livre ?10:14 Confusion sexualité / stimulation génitale11:59 Le couple, laboratoire de l'être13:26 Quand quitter une relation ?15:36 Pratiquer la détente18:15 Sauvage et sacré19:48 L'intelligence érotique : inné ou acquis ?21:05 L'amour : ça se travaille !22:41 Développement personnel vs développement relationnel25:06 L'espace de la relation27:13 Entrer dans la nudité émotionnelle28:27 Les grands tue-l'amour40:15 Comment devenir responsable de son désir ?42:44 Stages autour de la sexualité : attention !44:17 À quoi répond la sexualité ?46:52 Comment décrypter le langage de l'autre ?48:30 Comment cultiver son désir ?52:01 Ralentir pour vivre l'hyperconnexion53:40 Relation et espace du divinAvant-propos et précautions à l'écoute du podcast Découvrez Objectif Métamorphose, notre programme en 12 étapes pour partir à la rencontre de soi-même.Recevez chaque semaine l'inspirante newsletter Métamorphose par Anne GhesquièreFaites le TEST gratuit de La Roue Métamorphose avec 9 piliers de votre vie !Suivez nos RS : Insta, Facebook & TikTokAbonnez-vous sur Apple Podcast / Spotify / Deezer / CastBox/ YoutubeSoutenez Métamorphose en rejoignant la Tribu MétamorphosePhoto (c) LouSarda Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

On Soto's contract wearing on him